About

New Frontiers in 3D

Forging New Frontiers in 3D for Human Health

Toward Greater Human Physiological Relevance

There is growing interest in scalable 3D in vitro technologies and organ-on-a-chip systems that is causing a paradigm shift in how we approach drug discovery and development. But how do you separate the hype from practical innovations that are proven, tested and ready to implement for industry applications? New Frontiers in 3D symposia and roundtables offer an international virtual forum for you to meet with other leaders and innovators in the field of pharmaceutical drug discovery for discussing challenges and opportunities to advance preclinical research, with an emphasis on translational approaches, challenges, and successes.

Join the discussion and help shape the future of preclinical drug testing.

Who Should Attend

  • Pharma and biotech research scientists involved in drug discovery
  • Toxicologists engaged in drug safety testing
  • Research and innovation management.
  • Representatives from regulatory agencies

Join us to explore the latest advances in modeling human physiology

Sponsorship opportunities

Advancing human model systems for drug discovery

The New Frontiers in 3D teams aim to provide an educational and exploratory online forums on the latest advances in 3D cell culture technology for preclinical testing. We strive to provide a leaders and researchers who are actively engaged in working with in vitro models and testing platforms opportunities to discuss how we can harness emerging technology to better predict human in vivo responses to drugs and treatments earlier. If you have capabilities or technologies that would benefit our audience, our meetings enable you to showcase your solutions, network with participants, and source opportunities for partnerships.  

Past Conferences

Johns Hopkins University, Baltimore, MD USA
 October 13, 2016

The 2016 New Frontiers in 3D conference focused on 3D cell culture-based screening technologies and was organized by InSphero AG, National Center for Advancing Translational Sciences (NCATS), Centers for Alternatives to Animal Testing (CAAT), and Promega Corp. This inaugural event brought together more than 100 international experts in the translational application of advanced 3D model systems to drug discovery, safety testing, and beyond. The aim of the scientific advisory board was to foster discussion among speakers and attendees with diverse regulatory, industry, and academic perspectives of 3D models and screening technologies.  Speakers included:

  • Drug Discovery Track
    • Michael Gottesman, MD, Center for Cancer Research, NCI, NIH
    • Lesley A. Mathews Griner, PhD, Novartis Institutes for
      Biomedical Research
    • Robert Vries, PhD, Hubrecht Organoid Technology (HUB)
    • Madhu Lal-Nag, PhD, NCATS
    • Arno Amann, PhD, Medical University Innsbruck
    • Nikolaos Tsamandouras, PhD, MIT
  • Toxicology and Safety Testing Track
    • Thomas Hartung, MD, PhD, Johns Hopkins University Bloomberg School of Public Health
    • Philip Hewitt, PhD, Merck KGaA
    • Stephen S. Ferguson, PhD, National Institute of Environmental Health Sciences (NIEHS)
    • Olga Gordeeva, PhD, Russian Academy of Sciences
    • Jose A. Lebron, PhD, Merck
    • Piyush Bajaj, PhD, Pfizer
New Frontiers in 3D logo with date and location

Massachusetts Institute of Technology, Cambridge, MA
April 25, 2019

The 2019 New Frontiers in 3D symposium focused on forging new frontiers in human heath through practical applications of emerging 3D technologies, such as organs-on-chips, human disease modeling, drug safety testing, and alternatives for animal models. The meeting was organized by InSphero, and sponsored by BioSpyder, Alpco, Promega, and the Johns Hopkins University Centers for Alternatives to Animal Testing (CAAT), and InSphero, with the support of the Massachusetts Institute of Technology and MIT Samberg Conference Center. This event brought together more than 120 experts in the field and gave students an opportunity to showcase relevant research. Speakers included:

  • Patrick Guye, Cephalon Technologies, Program Chair
  • Matthias von Herrath, MD, Novo Nordisk and La Jolla Institute for Immunology
  • Armin Wolf, Prof., PhD, Technical Univ. of Kaiserlautern and InSphero AG
  • Lucia Liu, PhD, NIH/NCATS
  • Matthew Wagoner, PhD, Takeda
  • Olivier Frey, PhD, InSphero AG
  • Lena Smirnova, PhD, Johns Hopkins University/CAAT
  • Parastoo Khoshakhlagh, PhD, GC Therapeutics
  • Huu Tuan Nguyen, PhD, MIT Biological Engineering
  • Anne Carpenter, PhD, The Broad Institute of Harvard and MI